c-MYC rearrangement is frequently seen with concomitant adverse cytogenetic markers of CLL/SLL, such as del(11q) and/or del(17p)/monosomy 17, which helps explain the poor clinical outcomes in these patients [159]. Here, MYC is linked to B-cell chronic lymphocytic leukemia.